X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs NOVARTIS - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD NOVARTIS ORCHID PHARMA LTD/
NOVARTIS
 
P/E (TTM) x -0.2 318.8 - View Chart
P/BV x 0.2 35.3 0.5% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 ORCHID PHARMA LTD   NOVARTIS
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
NOVARTIS
Mar-18
ORCHID PHARMA LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs194758 25.6%   
Low Rs35579 6.0%   
Sales per share (Unadj.) Rs276.5228.4 121.1%  
Earnings per share (Unadj.) Rs-79.231.7 -249.6%  
Cash flow per share (Unadj.) Rs-43.532.8 -132.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs53.9297.1 18.2%  
Shares outstanding (eoy) m70.4524.69 285.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.42.9 14.1%   
Avg P/E ratio x-1.421.1 -6.9%  
P/CF ratio (eoy) x-2.620.4 -12.9%  
Price / Book Value ratio x2.12.2 94.4%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m8,06716,505 48.9%   
No. of employees `0002.80.7 419.2%   
Total wages/salary Rs m2,5271,445 174.8%   
Avg. sales/employee Rs Th6,956.18,441.3 82.4%   
Avg. wages/employee Rs Th902.52,163.6 41.7%   
Avg. net profit/employee Rs Th-1,993.01,173.1 -169.9%   
INCOME DATA
Net Sales Rs m19,4775,639 345.4%  
Other income Rs m4071,718 23.7%   
Total revenues Rs m19,8847,357 270.3%   
Gross profit Rs m1,103-63 -1,764.2%  
Depreciation Rs m2,51925 9,957.3%   
Interest Rs m5,22755 9,451.7%   
Profit before tax Rs m-6,2361,575 -395.9%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125792 -15.8%   
Profit after tax Rs m-5,580784 -712.1%  
Gross profit margin %5.7-1.1 -510.7%  
Effective tax rate %2.050.3 4.0%   
Net profit margin %-28.713.9 -206.2%  
BALANCE SHEET DATA
Current assets Rs m11,0149,522 115.7%   
Current liabilities Rs m32,0603,296 972.7%   
Net working cap to sales %-108.1110.4 -97.9%  
Current ratio x0.32.9 11.9%  
Inventory Days Days9537 259.1%  
Debtors Days Days3428 118.1%  
Net fixed assets Rs m29,44046 63,999.8%   
Share capital Rs m705123 570.9%   
"Free" reserves Rs m2,0437,213 28.3%   
Net worth Rs m3,8007,336 51.8%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51011,105 418.8%  
Interest coverage x-0.229.5 -0.7%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.5 82.5%   
Return on assets %-0.87.6 -10.1%  
Return on equity %-146.910.7 -1,374.9%  
Return on capital %-3.722.2 -16.8%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51361 12,398.2%   
Fx outflow Rs m5,6493,630 155.6%   
Net fx Rs m1,865-3,570 -52.2%   
CASH FLOW
From Operations Rs m1,6821,610 104.5%  
From Investments Rs m-9,860687 -1,435.3%  
From Financial Activity Rs m6,644-2,677 -248.2%  
Net Cashflow Rs m-1,535-380 404.4%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.6 2.0 230.0%  
FIIs % 3.3 1.6 206.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 21.5 257.2%  
Shareholders   84,811 41,647 203.6%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  AUROBINDO PHARMA  PFIZER  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Down 1%; Realty, Auto Stocks Tank(12:30 pm)

After opening the day flat share markets in India are trading on a negative note and are presently trading below the dotted line.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Sep 24, 2018 01:55 PM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - GSK PHARMA COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS